Antiepileptic effects of NBQX against soman-induced seizures. 1994

G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
Centre de Recherches du Service de Santé des Armées, Unité de Neurotoxicologie, La Tronche, France.

The ability of NBQX, a potent antagonist of AMPA glutamatergic receptors, to prevent or stop seizures induced by the organophosphate soman, an irreversible inhibitor of AChE, was studied in rats. NBQX administered concomitantly with soman prevents the onset of seizures (ED50: 29.2 mg kg-1, i.p.). Administered 5 min after the onset of seizures, NBQX greatly reduces the intensity of the epileptic activity. The same decrease of epileptic activity is observed, in the presence of atropine, when the administration of NBQX is delayed 15 min after the onset of seizures. NBQX thus appears as a promising antiepileptic candidate against soman-induced seizures. The roles of AMPA and muscarinic receptors in the onset and propagation of soman-induced epileptic activity are discussed.

UI MeSH Term Description Entries
D008297 Male Males
D011810 Quinoxalines Quinoxaline
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D001285 Atropine An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine. AtroPen,Atropin Augenöl,Atropine Sulfate,Atropine Sulfate Anhydrous,Atropinol,Anhydrous, Atropine Sulfate,Augenöl, Atropin,Sulfate Anhydrous, Atropine,Sulfate, Atropine
D012999 Soman An organophosphorus compound that inhibits cholinesterase. It causes seizures and has been used as a chemical warfare agent. Pinacolyl Methylphosphonofluoridate,Methylphosphonofluoridate, Pinacolyl
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
February 2001, Neurotoxicology,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
January 2014, Toxicology reports,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
May 2004, Toxicology and applied pharmacology,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
January 1993, Neuroscience and biobehavioral reviews,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
January 1989, Brain research bulletin,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
September 2022, Drug and chemical toxicology,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
January 1997, Journal of applied toxicology : JAT,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
December 2001, Journal of applied toxicology : JAT,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
April 2007, Toxicology and applied pharmacology,
G Lallement, and I Pernot-Marino, and A Foquin-Tarricone, and D Baubichon, and A Piras, and G Blanchet, and P Carpentier
April 2001, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!